Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GPR3 | P46089 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | NCF1 | P14598 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29756554 | 1.00 | KMT2A (0.44) | KMT2AKDM4EGPR3EGFRCYP1A2 | |
| Hydrochloric Acid SCHEMBL10828863 | 0.98 | KMT2A (0.43) | KMT2AKDM4EGPR3EGFRCYP1A2 | |
| SCHEMBL8501798 | 0.81 | KDM4E (0.37) | KMT2AKDM4EGPR3EGFRCYP1A2 | |
| SCHEMBL290894 | 0.79 | KDM4E (0.42) | KDM4EGPR3EGFRCYP1A2ALDH1A1 | |
| SCHEMBL1514912 | 0.79 | CYP1A2 (0.42) | KDM4EGPR3EGFRCYP1A2ALDH1A1 | |
| SCHEMBL2263641 | 0.79 | KDM4E (0.42) | KDM4EGPR3EGFRCYP1A2ALDH1A1 | |
| SCHEMBL9934866 | 0.79 | KDM4E (0.42) | KDM4EGPR3EGFRCYP1A2ALDH1A1 | |
| SCHEMBL6597830 | 0.79 | SORD (0.47) | KDM4EGPR3EGFRCYP1A2ALDH1A1 | |
| SCHEMBL9971234 | 0.79 | KDM4E (0.42) | KDM4EGPR3EGFRCYP1A2ALDH1A1 | |
| SCHEMBL30838793 | 0.79 | CYP1A2 (0.42) | KDM4EGPR3EGFRCYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106749046-A | The ketoxime ether derivative of 1,4 pentadiene 3 of one kind containing 4 (3H) quinazolinones and preparation method thereof | 贵州大学 | 2017-05-31 | — | — | CN | claimed |
| US-20250333412-A1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | SANOFI SA (FR) | 2025-10-30 | — | — | US | disclosed |
| US-12275733-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | SANOFI (FR) | 2025-04-15 | — | — | US | disclosed |
| US-20240182469-A1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | SANOFI (FR) | 2024-06-06 | — | — | US | disclosed |
| US-20240067632-A1 | WEE1 Degrading Compounds and Uses Thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-02-29 | — | — | US | disclosed |
| WO-2024006881-A1 | WEE1 DEGRADING COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-04 | — | — | WO | disclosed |
| US-11827633-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | SANOFI (FR) | 2023-11-28 | — | — | US | disclosed |
| CN-116804001-A | Quinazolinone derivative containing pyridinium and preparation method and application thereof | 江苏海洋大学 | 2023-09-26 | — | — | CN | disclosed |
| CN-110382496-B | Substituted pyrido [3,4-b ] indoles for the treatment of cartilage disorders | 赛诺菲 | 2022-08-09 | — | — | CN | disclosed |
| US-11130755-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | SANOFI (FR) | 2021-09-28 | — | — | US | disclosed |
| US-5283245-A | Antiinflammatory agent, antiallergens | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1994-02-01 | — | — | US | disclosed |
| CN-1079222-A | Pharmaceutical compositions containing quinoline and quinazoline derivatives and novel compounds thereof | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1993-12-08 | — | — | CN | disclosed |
| US-5236919-A | Inhibitorsof enzyme 5-lipoxygenase | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-08-17 | — | — | US | disclosed |
| US-5134148-A | Heterocycles for use as inhibitors of leukotrienes | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-07-28 | — | — | US | disclosed |
| US-5089495-A | Lipoxygenase inhibitors | IMPERIAL CHEMICAL INDUSTRIES PLC (FR) | 1992-02-18 | — | — | US | disclosed |
| CN-1046903-A | Process for preparing heterocyclic ether derivatives | ICI PLC (GB) | 1990-11-14 | — | — | CN | disclosed |
| EP-0385662-A2 | Heterocycles with inhibitory activity of 5-lipoxygenase | ZENECA LIMITED (GB) | 1990-09-05 | — | — | EP | disclosed |
| EP-0381375-A1 | Heterocyclic derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-08-08 | — | — | EP | disclosed |
| US-4904786-A | Quinoline compounds as antiallergic and antiinflammatory agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1990-02-27 | — | — | US | disclosed |
| US-4772703-A | LIPOXYGENASE INHIBITORS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1988-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827633-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | COL2A1, IDO1, COL1A1 | KMT2A 3542/4885KDM4E 706/4885GPR3 254/4885 |
| US-11130755-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | COL2A1, IDO1, COL1A1 | KMT2A 3542/4885KDM4E 706/4885GPR3 254/4885 |
| US-20240182469-A1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | COL2A1, IDO1, COL1A1 | KMT2A 3542/4885KDM4E 706/4885GPR3 254/4885 |
| US-12275733-B2 | Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders | COL2A1, IDO1, COL1A1 | KMT2A 3542/4885KDM4E 706/4885GPR3 254/4885 |
| US-20250333412-A1 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | COL2A1, IDO1, COL1A1 | KMT2A 3548/4885KDM4E 723/4885GPR3 252/4885 |
| US-20240067632-A1 | WEE1 Degrading Compounds and Uses Thereof | WEE1, WEE2, PPME1 | KMT2A 1212/4885KDM4E 376/4885GPR3 4300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.